Marksans Pharma Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cbxyhz8e4w4zn04ep207jfkd.pdf

Key Takeaways


U.S. Market: The Doubling Ambition

Mark Saldanha: "It's still a very small number for a market like U.S. So it's not something that is novel or is unique in any way but it's still at tip of the iceberg."

FY24 Performance & Q4 Headwinds


Margin Outlook & Profitability


Geographic & Portfolio Expansion

Mark Saldanha: "M&A is such an unpredictable thing even when we come to the last step it may not happen. So right now, there's nothing concrete to discuss or put pen to paper right now."

Guidance & Commitments

CommitmentSpecificsTimeline
Teva plant EBITDA breakevenBreakeven at EBITDA levelQ1 FY25
Teva plant capacity expansionIncrease to 500 crore tablets capacityBegin in H2 FY25
Volume growth15% volume growthFY25
Gross margin rangeSustain at 50% to 52%Ongoing
U.S. revenue doublingFrom $100 million to $200 million1–2 years
INR3,000 crores revenueAchieve with 20%+ marginFY26
U.S. monograph countGrow to 40+ monographsBy end of FY25
R&D spendAround 2% of revenueFY25
European market entryEnter European marketThis financial year (hopefully)
Net margin floor at scale15%+ net margin, maintainable or betterWhen INR3,000 crores revenue achieved

Key Metrics

MetricQ4 FY24
Operating revenue₹560 cr, +15.2% YoY
U.S. and North America revenue₹245 cr, +26.6% YoY
U.K. and EU formulation revenue₹230.8 cr, +12.9% YoY
Australia and New Zealand revenue₹63.3 cr, stable YoY
Gross margin51.8%
EBITDA₹109.6 cr, +0.1% YoY and -17.6% QoQ
EBITDA margin19.6%
FY24 operating revenue₹2,177 cr, +17.6% YoY
FY24 EBITDA₹459 cr, +35% YoY
FY24 EBITDA margin21.1%, +274 bps YoY
FY24 PAT₹314.9 cr, +18.7% YoY
FY24 EPS₹6.92
FY24 gross margin52.3%, +207 bps YoY
FY24 cash from operations₹230 cr
FY24 free cash flow₹21.6 cr
FY24 capex₹208 cr, including ₹125 cr in Teva facility
Cash balance₹674 cr as of March 31, 2024
Red Sea crisis cost impact~₹9 cr in Q4
U.S. revenue mix (OTC/Rx)80% OTC, ~20% Rx
U.S. EBITDA margin10%+
Ibuprofen revenue contribution~15% of total revenue
U.S. monographs25-30 currently, expected 40+ by end of FY25
Teva plant capacity commercialized300 crore units, next phase to 5-plus billion units
Dividend per share₹0.6, 60% of ₹1 face value